NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals is a specialty-pharma micro-cap developing CNS and critical-care therapies. The near-term equity story is the FDA review of NRx's abbreviated new drug application (ANDA) for preservative-free ketamine (branded KETAFREE/NRX-100) for depression and PTSD — a specific regulatory event, not a broad pipeline bet.

• Revenue was $1.07M in Q1 — essentially zero from an equity perspective; this ticker is trading entirely on regulatory optionality, not business economics.
• The FDA confirmed no major deficiencies in the first-cycle ketamine ANDA review, with only a packaging attestation left on a vial that has already been used in ~11.9M doses — first-cycle ANDA approvals hit only 14-18% of the time historically, so a clean-review signal here is materially above base rate.
• Sits at the 55th percentile of the 52-week range but is 26% above the 200-day trend — the tape is priced for optionality; not front-running the approval violently, but not discounting it either.
• Analyst 2027 revenue estimate is $166M vs $14M in 2026 — a ~12x step-up predicated specifically on the ketamine launch happening; the entire model swings on the regulatory outcome.

What resolves the coil upward is FDA action letter approving KETAFREE (which triggers the launch and the analyst 2027 revenue ramp), or a specific milestone announcement on the pipeline. What breaks it down is a Complete Response Letter (CRL) or a delay beyond fast-track timing, either of which pushes the whole 2027 revenue thesis out by at least a year and forces a fresh capital raise at a lower price.